Titlebook: Leukotrienes and Prostacyclin; F. Berti,G. Folco,G. P. Velo Book 1983 Springer Science+Business Media New York 1983 Prostaglandin.cancer.i

MIR

Pharmacology of Leukotriene C4 in Guinea-Pig,ions is widely recognized. The recent discovery that some arachidonic acid metabolites, derived from 5-1ipoxigenase pathway, can display potent biological actions which are similar to that of slow reacting substance of anaphylaxis (SRS-A), stimulated a fresh interest in the field of asthma and other

粗野

monochromatic

Inhibition of Arachidonic Acid Metabolism,ons including inflammation, asthma, Bartter’s syndrome, dysmenorrhoea, threatened abortion and premature labour. Thus, compounds which inhibit metabolism of arachidonic acid have a wide therapeutic potential. Additionally, such inhibitors should prove invaluable to the experimental investigator to e

LOPE

Adenocarcinoma

6-Keto-Prostaglandin E1: Biosynthesis and Circulatory Effects,GI.). Like PGI., 6-keto-PGE. is potent in stimulating renin secretion [l–3], inhibiting platelet aggregation [4], and reducing blood pressure and vascular resistance in diverse regional circulations [5, 6]. In this chaper, we present evidence that 6-keto-PGE. may arise during the course of metabolic

Canary

不公开

An , Aggregometer, it is generally accepted that . data does not always reflect . data [2], fewer studies have been undertaken on platelets .. Such, . studies are limited by the cumbersome and invasive nature of existing techniques [3] which has prompted development of a simple, minimally invasive technique for the c

anthesis

Inhibition of Platelet Aggregation and Cardiovascular Effect of 5E-13,14-Didehydro Carboprostacyclisive effect in animals and humans [1, 2, 3], many efforts have been made to synthesize PGI.-derivatives that are chemically stable and which possibly have longer lasting action. The first goal has been reached easily enough and carboprostacyclin [4, 5], 10,10-difluoro-13,14-dehydroprostacyclin [6] a

水汽

Conjuction

Clinical Use of Prostacyclin in Vascular Disease,stration of prostacyclin to man [5, 25] and were confirmed in later studies [7, 14]. The action of pros-tacyclin on platelets is manifested in its anti-aggregatory and disaggregatory properties [5, 18, 26]. The former are seen as a marked inhibition of ADP- or collagen-induced platelet aggregation i